Salīdzināt metodes

	CAM tests	MTT/MTS testēšana
Nozare	Biomateriāli	Biomateriāli
Saime	Process / pipeline	Process / pipeline
Izcelsmes gads	1974	1983
Autors	Judah Folkman	Tatsuro Mosmann
Tips	Developmental biology assay	Colorimetric assay
Pirmavots	Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.	Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), 55-63.
Citi nosaukumi	chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, tetrazolium assay, mitochondrial activity assay
Saistītās	4	4
Kopsavilkums	The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.	The MTT assay, introduced by Tatsuro Mosmann in 1983, is a colorimetric method for quantifying cell viability and proliferation by measuring mitochondrial metabolic activity. The method detects the conversion of the water-soluble tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by active mitochondria, producing an insoluble purple formazan precipitate proportional to the number of viable cells. The related MTS assay, which does not require solubilization, offers improved kinetics and is now widely adopted in both academic research and pharmaceutical development.